[1. R. S. Herbst, Review of epidermal growth factor receptor biology, Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 21-26; DOI: 10.1016/j.ijrobp.2003.11.041.10.1016/j.ijrobp.2003.11.04115142631]Search in Google Scholar
[2. H. Zhang, A. Berezov, Q. Wang, G. Zhang, J. Drebin, R. Murali and M. I. Greene, ErbB receptors: from oncogenes to targeted cancer therapies, J. Clin. Invest. 117 (2007) 2051-2058; DOI: 10.1172/JCI32278.10.1172/JCI32278193457917671639]Search in Google Scholar
[3. A. Kendall, R. Lord and N. Maisey, Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer, Recent. Pat. Anticancer Drug Discov. 5 (2010) 142-151; DOI: 10. 2174/157489210790936270.10.2174/15748921079093627019954416]Search in Google Scholar
[4. M. S. Ramakrishnan, A. Eswaraiah, T. Crombet, P. Piedra, G. Saurez, H. Iyer and A. S. Arvind, Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin, mAbs 1 (2009) 41-48; DOI: 10.4161/mabs.1.1.7509.10.4161/mabs.1.1.7509271518120046573]Search in Google Scholar
[5. R. C. Chatelier, R. G. Ashcroft, C. J. Lloyd, E. C. Nice, R. H. Whitehead, W. H. Sawyer and A.W. Burgess, Binding of fluoresceinated epidermal growth factor to A431 cell sub-populations studied using a model-independent analysis of flow cytometric fluorescence data, EMBO 5 (1986) 1181-1186.10.1002/j.1460-2075.1986.tb04344.x11669253015587]Search in Google Scholar
[6. N. B. S. Abid, Z. Rouis, F. Nefzi, N. Souelah and M. Aouni, Evaluation of dimethylthiazol diphenyl tetrazolium bromide and propidium iodide inclusion assays for the evaluation of cell viability by flow cytometry, J. Appl. Pharm. Sci. 2 (2012) 10-14; DOI: 10.7324/JAPS.2012.2525.10.7324/JAPS.2012.2525]Search in Google Scholar
[7. A. L. Givan, Critical Aspects of Staining for Flow Cytometry, in Living Color: Protocols in Flow Cytometry and Cell Sorting (Eds. R. Diamond and S. DeMaggio), 1st ed., Springer, Berlin 2000, pp. 142-164.]Search in Google Scholar
[8. W. K. Boland and G. Bebb, Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity, Expert Opin. Biol. Ther. 9 (2009) 1-8; DOI: 10.1517/14712590903110709.10.1517/1471259090311070919624281]Search in Google Scholar
[9. J. M. Reichert, Antibody-based therapeutics to watch in 2011, mAbs 3 (2011) 76-99; DOI: 10.4161/mabs.3.1.13895.10.4161/mabs.3.1.13895303801421051951]Search in Google Scholar
[10. R. I. Freshney, Basic Principles of Cell Culture, in Culture of Cells for Tissue Engineering (Eds. G. Vunjak-Novakovic and R. I. Freshney), John Wiley, New York 2006, pp. 11-14.10.1002/0471741817.ch1]Search in Google Scholar
[11. G. Rothe, Technical Background and Methodological Principles of Flow Cytometry, in Cellular Diagnostics. Basics, Methods and Clinical Applications of Flow Cytometry (Eds. U. Sack, A. Tarnok and G. Rothe), Karger, Basel 2009, pp. 53-88; DOI: 10.1159/000209156.10.1159/000209156]Search in Google Scholar
[12. G. N. Gill and C. S. Lazar, Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells, Nature 293 (1981) 305-307.10.1038/293305a06268987]Search in Google Scholar
[13. L. Nikfarjam and P. Farzaneh, Prevention and detection of mycoplasma contamination in cell culture, Cell J. (Yakhteh) 13 (2012) 203-212.]Search in Google Scholar
[14. T. Mammone, D. Gan and R. Foyouzi-Youssefi, Apoptotic cell death increases with senescence in normal human dermal fibroblast cultures, Cell Biol. Int. 30 (2006) 903-909; DOI: 10.1016/j.cellbi.2006.06.010.10.1016/j.cellbi.2006.06.01016904918]Search in Google Scholar
[15. S. Gupta, S. R. Indelicato, V. Jethwa, T. Kawabata, M. Kelley, A. R. Mire-Sluis, S. M. Richards, B. Rup, E. Shores, S. J. Swanson and E. Wakshull, Recommendations for the design optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics, J. Immunol. Met. 321 (2007) 1-18; DOI: 10.1016/j.jim.2004.06.002.10.1016/j.jim.2004.06.00215251407]Search in Google Scholar